XML 52 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Income (Loss) Per Share (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2025
Earnings Per Share [Abstract] |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the computation of basic and diluted net income (loss) per share for the three and six months ended March 31, 2025 and 2024.
|  | Three Months Ended March 31, |  | Six Months Ended March 31,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
|  | (in thousands, except per share amounts)
Numerator: |  |  |  |  |  |  |  |
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc. |  | $ | 370,445 |  |  | $ | (125,300) |  |  | $ | 197,360 |  |  | $ | (258,164) |
Denominator: |  |  |  |  |  |  |  |
Weighted-average basic shares outstanding (1) |  | 133,363 |  |  | 123,285 |  |  | 129,059 |  |  | 115,307 |
Effect of dilutive securities |  | 1,121 |  |  | — |  |  | 1,206 |  |  | — |
Weighted-average diluted shares outstanding (1) |  | 134,484 |  |  | 123,285 |  |  | 130,265 |  |  | 115,307 |
Basic net income (loss) per share |  | $ | 2.78 |  |  | $ | (1.02) |  |  | $ | 1.53 |  |  | $ | (2.24) |
Diluted net income (loss) per share |  | $ | 2.75 |  |  | $ | (1.02) |  |  | $ | 1.52 |  |  | $ | (2.24) |
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net income (loss) per share because to include them would be anti-dilutive.
|  | Three Months Ended March 31, |  | Six Months Ended March 31,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
|  | (in thousands)
Options |  | 760 |  |  | 595 |  |  | 750 |  |  | 657 |
Restricted stock units |  | 5,289 |  |  | 3,411 |  |  | 4,567 |  |  | 3,931 |
Total |  | 6,049 |  |  | 4,006 |  |  | 5,317 |  |  | 4,588 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration